{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:04:06Z","timestamp":1782230646325,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["19-0232"],"award-info":[{"award-number":["19-0232"]}],"id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","award":["21006"],"award-info":[{"award-number":["21006"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2018071"],"award-info":[{"award-number":["APP2018071"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2011139"],"award-info":[{"award-number":["GNT2011139"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1016701"],"award-info":[{"award-number":["1016701"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1176175"],"award-info":[{"award-number":["APP1176175"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020731","name":"Walter and Eliza Hall Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100149","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:07:44Z","timestamp":1754323664000},"page":"100149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["MNT: a new target for AML"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-3636","authenticated-orcid":false,"given":"Karla C.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5195-5033","authenticated-orcid":false,"given":"Veronique","family":"Litalien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1946-5161","authenticated-orcid":false,"given":"Sarah T.","family":"Diepstraten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6558-1456","authenticated-orcid":false,"given":"Michelle","family":"Jahja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9711-9769","authenticated-orcid":false,"given":"Fiona C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-1201","authenticated-orcid":false,"given":"Gemma L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-3451","authenticated-orcid":false,"given":"Suzanne","family":"Cory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bneo.2025.100149_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"10.1016\/j.bneo.2025.100149_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11101003","article-title":"New drugs bringing new challenges to AML: a brief review","volume":"11","author":"Yeoh","year":"2021","journal-title":"J Pers Med"},{"issue":"22","key":"10.1016\/j.bneo.2025.100149_bib3","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bneo.2025.100149_bib4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bneo.2025.100149_bib5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1097-2765(02)00741-4","article-title":"MLL targets SET domain methyltransferase activity to Hox gene promoters","volume":"10","author":"Milne","year":"2002","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.bneo.2025.100149_bib6","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1097-2765(02)00740-2","article-title":"ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation","volume":"10","author":"Nakamura","year":"2002","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.bneo.2025.100149_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2020.194503","article-title":"MLL fusion proteins and transcriptional control","volume":"1863","author":"Slany","year":"2020","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"17","key":"10.1016\/j.bneo.2025.100149_bib8","first-page":"6480","article-title":"MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation","volume":"61","author":"Schreiner","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.bneo.2025.100149_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.leu.2402804","article-title":"Transcriptional activation is a key function encoded by MLL fusion partners","volume":"17","author":"Zeisig","year":"2003","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.bneo.2025.100149_bib10","doi-asserted-by":"crossref","first-page":"25208","DOI":"10.18632\/oncotarget.8199","article-title":"Differential regulation of the c-Myc\/Lin28 axis discriminates subclasses of rearranged MLL leukemia","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bneo.2025.100149_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bbagrm.2014.05.016","article-title":"Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis","volume":"1849","author":"Diolaiti","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"10.1016\/j.bneo.2025.100149_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrc3984","article-title":"MYC: connecting selective transcriptional control to global RNA production","volume":"15","author":"Kress","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.bneo.2025.100149_bib13","first-page":"1915","article-title":"Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis","volume":"6","author":"Askew","year":"1991","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bneo.2025.100149_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0092-8674(92)90123-T","article-title":"Induction of apoptosis in fibroblasts by c-myc protein","volume":"69","author":"Evan","year":"1992","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bneo.2025.100149_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ccr.2008.10.018","article-title":"Distinct thresholds govern Myc's biological output in vivo","volume":"14","author":"Murphy","year":"2008","journal-title":"Cancer Cell"},{"issue":"6299","key":"10.1016\/j.bneo.2025.100149_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/348331a0","article-title":"Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2","volume":"348","author":"Strasser","year":"1990","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.bneo.2025.100149_bib17","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1073\/pnas.0401471101","article-title":"Bim is a suppressor of Myc-induced mouse B cell leukemia","volume":"101","author":"Egle","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bneo.2025.100149_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1146\/annurev.cellbio.16.1.653","article-title":"The Myc\/Max\/Mad network and the transcriptional control of cell behavior","volume":"16","author":"Grandori","year":"2000","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100149_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1101\/gad.11.1.44","article-title":"Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites","volume":"11","author":"Hurlin","year":"1997","journal-title":"Genes Dev"},{"issue":"18","key":"10.1016\/j.bneo.2025.100149_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184682","article-title":"The multiple faces of MNT and its role as a MYC modulator","volume":"13","author":"Lia\u00f1o-Pons","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.bneo.2025.100149_bib21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0092-8674(95)90355-0","article-title":"Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3","volume":"80","author":"Ayer","year":"1995","journal-title":"Cell"},{"issue":"pt 2","key":"10.1016\/j.bneo.2025.100149_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1242\/jcs.02815","article-title":"Of Myc and Mnt","volume":"119","author":"Hooker","year":"2006","journal-title":"J Cell Sci"},{"issue":"11","key":"10.1016\/j.bneo.2025.100149_bib23","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1158\/0008-5472.CAN-05-2683","article-title":"Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression","volume":"66","author":"Toyo-oka","year":"2006","journal-title":"Cancer Res"},{"issue":"48","key":"10.1016\/j.bneo.2025.100149_bib24","doi-asserted-by":"crossref","first-page":"19685","DOI":"10.1073\/pnas.1206406109","article-title":"A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis","volume":"109","author":"Link","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.bneo.2025.100149_bib25","first-page":"1019","article-title":"Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis","volume":"135","author":"Nguyen","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100149_bib26","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/s41418-023-01119-y","article-title":"MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis","volume":"30","author":"Nguyen","year":"2023","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.bneo.2025.100149_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","article-title":"MYC protein expression is an important prognostic factor in acute myeloid leukemia","volume":"60","author":"Ohanian","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.bneo.2025.100149_bib28","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/emboj.2011.307","article-title":"Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases","volume":"30","author":"Strasser","year":"2011","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.bneo.2025.100149_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.bneo.2025.100149_bib30","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/hmg\/ddh116","article-title":"Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome","volume":"13","author":"Toyo-oka","year":"2004","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.bneo.2025.100149_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gng012","article-title":"Rapid generation of inducible mouse mutants","volume":"31","author":"Seibler","year":"2003","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"10.1016\/j.bneo.2025.100149_bib32","doi-asserted-by":"crossref","first-page":"10887","DOI":"10.1073\/pnas.93.20.10887","article-title":"Ligand-activated site-specific recombination in mice","volume":"93","author":"Feil","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.bneo.2025.100149_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.258","article-title":"Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice","volume":"7","author":"Bilardi","year":"2016","journal-title":"Cell Death Dis"},{"issue":"7","key":"10.1016\/j.bneo.2025.100149_bib34","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41418-018-0209-1","article-title":"Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice","volume":"26","author":"Anstee","year":"2019","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.bneo.2025.100149_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V70.1.192.192","article-title":"Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines","volume":"70","author":"Lange","year":"1987","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100149_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.2910260208","article-title":"Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)","volume":"26","author":"Tsuchiya","year":"1980","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.bneo.2025.100149_bib37","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.leu.2400768","article-title":"Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23)","volume":"11","author":"Matsuo","year":"1997","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bneo.2025.100149_bib38","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/sj.leu.2403899","article-title":"Cell line OCI\/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin","volume":"19","author":"Quentmeier","year":"2005","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2025.100149_bib39","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","article-title":"An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo","volume":"10","author":"Aubrey","year":"2015","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.bneo.2025.100149_bib40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-23-0402","article-title":"Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival, and metastasis of a broad range of cancer cells","volume":"14","author":"Wang","year":"2024","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.bneo.2025.100149_bib41","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100149_bib42","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/leu.2012.363","article-title":"Cell of origin determines clinically relevant subtypes of MLL-rearranged AML","volume":"27","author":"Krivtsov","year":"2013","journal-title":"Leukemia"},{"issue":"7104","key":"10.1016\/j.bneo.2025.100149_bib43","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","article-title":"Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9","volume":"442","author":"Krivtsov","year":"2006","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bneo.2025.100149_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.409","article-title":"Impact of conditional deletion of the pro-apoptotic BCL-2 family member BIM in mice","volume":"5","author":"Herold","year":"2014","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.bneo.2025.100149_bib45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev"},{"issue":"8","key":"10.1016\/j.bneo.2025.100149_bib46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.trecan.2016.07.001","article-title":"Targeting BCL-2-like proteins to kill cancer cells","volume":"2","author":"Cory","year":"2016","journal-title":"Trends Cancer"},{"issue":"24","key":"10.1016\/j.bneo.2025.100149_bib47","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bneo.2025.100149_bib48","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/emboj\/17.2.384","article-title":"Bim: a novel member of the Bcl-2 family that promotes apoptosis","volume":"17","author":"O'Connor","year":"1998","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/j.bneo.2025.100149_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"10.1016\/j.bneo.2025.100149_bib50","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2019003262","article-title":"Epigenetic therapies in acute myeloid leukemia: where to from here?","volume":"134","author":"Fennell","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100149_bib51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2025.100149_bib52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/PPO.0000000000000571","article-title":"Menin inhibitors in acute myeloid leukemia-what does the future hold?","volume":"28","author":"Swaminathan","year":"2022","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.bneo.2025.100149_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.bneo.2025.100149_bib54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOH.0000000000000796","article-title":"The future of HOXA- expressing leukemias: menin inhibitor response and resistance","volume":"31","author":"Wenge","year":"2024","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100149_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2025.100149_bib56","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bneo.2025.100149_bib57","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100149_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"issue":"15","key":"10.1016\/j.bneo.2025.100149_bib59","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100149_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/genes8060151","article-title":"MYC Deregulation in Primary Human Cancers","volume":"8","author":"Kalkat","year":"2017","journal-title":"Genes (Basel)"},{"issue":"3","key":"10.1016\/j.bneo.2025.100149_bib62","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cels.2018.03.003","article-title":"Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas","volume":"6","author":"Schaub","year":"2018","journal-title":"Cell Syst"},{"key":"10.1016\/j.bneo.2025.100149_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1142111","article-title":"Strategies to target the cancer driver MYC in tumor cells","volume":"13","author":"Weber","year":"2023","journal-title":"Front Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:40:57Z","timestamp":1764121257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000846"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100149","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MNT: a new target for AML","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100149"}}